A recent study reported the initial results of a phase I trial involving the administration of ivosidenib or enasidenib, in combination with standard induction and consolidation chemotherapy, to the de novo diagnosed AML patients bearing either IDH1 or IDH2 mutations [392]. Here, IDH1 is linked to acute myeloid leukemia.